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Purpose
To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal
carcinoma, we compared the treatment outcomes of patients treated with curative radio-
therapy with or without chemotherapy.
Materials and Methods
From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002
stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals
in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant
chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in
80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. 
Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy
to 74.2 Gy (median, 70 Gy).
Results
Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last follow-
up, 13 patients had died and 32 had experienced treatment failure; locoregional failure 
occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free
survival, distant metastasis-free survival, progression-free survival, and overall survival were
86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the 
significant prognostic factors were concurrent chemotherapy and N stage for locoregional
relapse-free survival, concurrent chemotherapy for progression-free survival, and age and
N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved
distant metastasis-free survival.
Conclusion
Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival
and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant
chemotherapy failed to improve either.
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Introduction
Early-stage nasopharyngeal carcinoma (NPC) is tradition-
ally treated with radiotherapy (RT) alone which achieves
high overall survival (OS) rates. However, treatment 
outcome after RT alone in early-stage NPC is not always 
satisfactory in terms of locoregional control and distant
metastasis. Chua et al. [1] reported results of 141 early-stage
NPC patients treated with RT alone and found that stage II
patients showed significantly poorer outcomes. The 10-year
disease-specific survival, recurrence-free survival, local 
control, regional control, and distant control rates of stage I
patients were 98%, 94%, 96%, 98%, and 98%, respectively,
and the corresponding 10-year survival rates of stage II 
patients were 60%, 51%, 78%, 93%, and 64%, respectively. In
addition, parapharyngeal extension [2,3], N1 [1,4] or T2N1
(1992 Fuzhou, China staging system) [5] increased the inci-
dence of distant metastasis or were associated with poorer
survival in early-stage NPC.
Chemotherapy (CTx) has been used before, during, or after
RT in selected early stage NPC at the physician’s discretion.
Concurrent CTx is considered to improve locoregional 
control, and Xu et al. [6] retrospectively found that the 
locoregional control rate in T2N1 NPC was significantly
higher for concurrent CTx than RT alone (91.5% vs. 77.3%,
p=0.008). On the other hand, neoadjuvant CTx has been used
to reduce distant metastasis, but results of two studies about
the role of neoadjuvant CTx in early-stage NPC were contra-
dictory. Neoadjuvant CTx decreased distant metastasis and
improved OS in a subgroup analysis of two randomized 
trials [7], but not in a retrospective study [8]. Hence, the role
of CTx in early-stage NPC is ill-defined.
To define the roles of neoadjuvant and concurrent CTx on
patterns of failure and survival in stage II NPC patients, we
retrieved and analyzed the data of stage II NPC patients 
collected in a database for the patterns of care study 
conducted by Head and Neck Study Group of the Korean 
Society for Radiation Oncology (KROG 11-09).
Materials and Methods
The Institutional Review Boards of all participating hospi-
tals approved this retrospective study and waived the 
requirement for informed patient consent.
1. Patients
From 2004 to 2011, 804 patients with nasopharyngeal 
cancer were treated at 15 hospitals in South Korea, and of
these, 138 patients from 12 hospitals met the following study
eligibility criteria: biopsy-proven NPC, American Joint Com-
mittee on Cancer (AJCC) 2002 stage II (T2N0, T1N1, or
T2N1), completion of curative RT, and available information
on patterns of failure and survival. Patient and tumor char-
acteristics are listed in Table 1. Patients with a follow-up 
period of less than 12 months without any event were 
excluded.
2. Pretreatment workup
All patients underwent computed tomography (CT,
n=129) and/or magnetic resonance imaging (MRI, n=104) of
the head and neck. For the systemic work-up, bone scan
(n=23) and abdominal ultrasonography or CT (n=13) were
used. Positron emission tomography-computed tomography
(PET-CT) was used in 79.0% of the patients (109/138). After
Table 1. Patients and tumor characteristics
Characteristic No. (%)
Age (yr) ! 60 99 (71.7)
> 60 39 (28.3)
Gender Female 40 (29.0)
Male 98 (71.0)
ECOG 0 31 (22.5)
1 95 (68.8)
2 5 (3.6)
Unknown 7 (5.1)
Smoking No 69 (50.0)
Yes 58 (42.0)
Unknown 11 (8.0)
Histology WHO 1 19 (13.8)
WHO 2 39 (28.3)
WHO 3 80 (58.0)
Histology Keratinizing 19 (13.8)
Non-keratinizing 119 (86.2)
Epstein-Barr virus Negative 9 (6.5)
Positive 28 (20.3)
Unknown 101 (73.2)
T stage 1 68 (49.3)
2 70 (50.7)
N stage 0 21 (15.2)
1 117 (84.8)
TNM stage T1N1 68 (49.3)
T2N0 21 (15.2)
T2N1 49 (35.5)
ECOG, Eastern Cooperative Oncology Group; WHO,
World Health Organization. 
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PET-CT became reimbursable by Korean National Health 
Insurance System in June 2006, it became routine. 
3. Treatment
RT techniques included 2-dimensional RT alone (2D-RT)
in three patients, 2D-RT followed by 3-dimensional confor-
mal RT (3D-CRT) or intensity-modulated radiation therapy
(IMRT) in six, 3D-CRT alone in 50, 3D-CRT followed by
stereotactic body RT (SBRT) in one, and IMRT alone in 78.
Total dose ranged from 64 to 74.2 Gy (median, 70 Gy), after
excluding one patient given 100.2 Gy by 3D-CRT and SBRT.
RT was given once daily at a median fraction size of 2.12 Gy
(1.8 Gy in 32, 2.0 Gy in 35, 2.12 Gy in 24, 2.20 Gy in 15, 2.25
Gy in 15, and 2.4 Gy in 17).
CTx was used in neoadjuvant, concurrent, and adjuvant
settings. Neoadjuvant CTx was used in 17.4% of patients
(24/138) and concurrent CTx in 70.3% (97/138). Accordingly,
there were four treatment groups: RT alone in 34 patients,
neoadjuvant CTx followed by RT alone in seven patients,
concurrent chemoradiotherapy (CCRT) in 80 patients, and
neoadjuvant CTx followed by CCRT (neo-CCRT) in 17 
patients. During RT, most patients were given cisplatin
weekly or every 3 to 4 weeks. Cisplatin-based combination
regimens were used for neoadjuvant CTx. Neoadjuvant CTx
regimens used 5-fluorouracil and cisplatin in 11 patients, 
docetaxel and cisplatin in six, 5-fluorouracil, docetaxel and
cisplatin in four, and other taxane-containing regimens in
three. Concurrent CTx regimens were cisplatin every 3 to 4
weeks in 45 patients, weekly cisplatin in 40, 5-fluorouracil
and cisplatin in five, and other regimens in seven. Adjuvant
CTx was used in 30.4% of the patients (42/138): 39 patients
in CCRT group, two in neo-CCRT group, and one in RT
alone group. Adjuvant CTx regimens were 5-fluorouracil
and cisplatin in 38 patients and taxane-containing regimens
in three.
Planned neck dissection was not performed in all patients.
Instead, three patients with partial response underwent neck
dissection at 37, 48, and 101 days after completing RT. These
patients were not considered to have regional recurrence.
4. Statistical analysis
The chi-square test or Fisher exact test and the Student 
Table 2. Comparison of patient and tumor characteristics
Characteristic Neoadjuvant CTx Concurrent CTx
No Yes p-value No Yes p-value
Age (yr) ! 60 80 19 0.374 27 72 0.318
> 60 34 5 14 25
Gender Male 79 19 0.333 31 67 0.439
Female 35 5 10 30
Histology Keratinizing 18 1 0.196 4 15 0.374
Non-keratinizing 96 23 37 82
T stage 1 56 12 0.938 18 50 0.412
2 58 12 23 47
N stage 0 21 0 0.025 12 9 0.003
1 93 24 29 88
TNM stage T1N1 56 12 0.030 18 50 0.010
T2N0 21 0 12 9
T2N1 37 12 11 38
Neoadjuvant CTx No - - - 34 80 0.949
Yes - - 7 17
Concurrent CTx No 34 7 0.949 - - -
yes 80 17 - -
Adjuvant CTx No 74 22 0.010 40 56 < 0.001
yes 40 2 1 41
RT  technique 2D-RT 6 3 0.190 4 5 0.450
3D-CRT or IMRT 108 21 37 92
CTx, chemotherapy; RT, radiotherapy; 2D-RT, 2-dimensional radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy;
IMRT, intensity-modulated radiation therapy. 
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t test or one-way ANOVA were used to evaluate group 
differences among categorical or continuous variables as 
appropriate. The duration of locoregional relapse-free 
survival (LRRFS), distant metastasis-free survival (DMFS),
progression-free survival (PFS), and OS rates was calculated
from treatment start to the date of the first event or the date
of last follow-up. Survival curves were calculated using the
Kaplan-Meier method. Log-rank tests and the Cox propor-
tional hazard model using backward stepwise elimination
procedure to remove variables with a p-value of " 0.10 were
used to determine the prognostic significance of variables.
IBM SPSS ver. 22 (IBM Co., Armonk, NY) was used for analy-
sis, and p-values of < 0.05 were considered significant.
Results
1. Patient and tumor characteristics
Patient and tumor characteristics, except N stage and the
use of adjuvant CTx, were not significantly different between
neoadjuvant CTx and concurrent CTx groups (Table 2).
Neoadjuvant CTx was used only in patients with N1 disease
(20.5% vs. 0%, p=0.025). Concurrent CTx was used more 
frequently in patients with N1 disease (75.2% vs. 42.9%,
p=0.003). Adjuvant CTx was predominantly used in concur-
rent CTx group (42.3% vs. 2.4%, p < 0.001).
2. Patterns of failure and survival
Median follow-up in the 138 patients was 48 months
(range, 7 to 97 months). Thirty-two patients experienced
treatment failure; locoregional failure in 14 (9 local, 4 
regional, and 1 locoregional), distant failure in 16, and both
in two.
Of the 14 patients with locoregional relapse only, salvage
surgery (n=3), RT (n=6), or both (n=1) were applied, and four
received additional CTx. One patient was treated with CTx
alone. Four patients died at 16, 22, 35, and 45 months after
diagnosis of recurrence and eight patients remained alive at
12 to 84 months after recurrence (median, 30 months). OS
rate after diagnosis of locoregional recurrence was 63.0% at
3 years. Of the 18 patients with distant metastasis, palliative
CTx was administered in 15 patients. The OS rate after diag-
nosis of distant metastasis was 57.6% at 3 years. At the last
follow-up, 13 of the 138 patients had died: nine of distant
metastasis, two of local recurrence, one of a non-nasopharyn-
geal cause, and one of unknown cause. 
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Fig. 1.  Locoregional relapse-free, distant metastasis-free,
progression-free, and overall survival curves for all 
patients.
Table 3. Univariate and multivariate analyses of prognostic factors for survival endpoints
Locoregional Distant Progression-free OverallVariable relapse-free metastasis-free
Uni Multi Uni Multi Uni Multi Uni Multi
Age (! 60 yr vs. > 60 yr) 0.111 - 0.495 - 0.150 - 0.014 0.041
Gender (male vs. female) 0.042 0.087 0.766 - 0.268 - 0.548 -
Histology (keratinizing vs. 0.936 - 0.721 - 0.862 - 0.605 -
non-keratinizing)
Neoadjuvant chemotherapy (no vs. yes) 0.477 - 0.453 - 0.365 - 0.717 -
Concurrent chemotherapy (no vs. yes) < 0.001 0.004 0.765 - 0.007 0.012 0.256 -
T stage (T1 vs. T2) 0.243 - 0.163 0.172 0.056 0.077 0.155 -
N stage (N0 vs. N1) 0.002 0.039 0.757 - 0.041 - 0.007 0.029
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3. Prognostic factors
Fig. 1 shows survival curves and Table 3 shows the results
of univariate and multivariate analyses of prognostic factors.
OS rates were 93.7% at 3 years and 88.2% at 5 years. Age and
N stage were significant prognostic factors in both univariate
and multivariate analysis. However, neither concurrent CTx
nor neoadjuvant CTx improved OS.
PFS rates were 77.0% at 3 years and 74.4% at 5 years. 
Concurrent CTx and N stage were significantly associated
with PFS by univariate analysis, but only concurrent CTx
was significant in multivariate analysis. Fig. 2A shows the
PFS curves according to the use of concurrent CTx.
LRRFS rates were 90.5% at 3 years and 86.2% at 5 years.
Significant variables were gender, concurrent CTx, and N
stage in univariate analysis. Concurrent CTx and N stage
were significantly associated with LRRFS in multivariate
analysis. Neoadjuvant CTx did not improve locoregional
control. Fig. 2B shows LRRFS curves according to the use of
concurrent CTx: 3- and 5-year LRRFS of each group were
78.8% vs. 95.7% and 66.6% vs. 95.7%, respectively. DMFS
rates were 86.8% at 3 years and 85.5% at 5 years. No signifi-
cant prognostic factor was identified in univariate or univari-
ate analysis.
Discussion
In this study, concurrent CTx significantly improved
LRRFS and PFS in stage II stage NPC, whereas neoadjuvant
CTx did not. However, neither neoadjuvant nor concurrent
CTx reduced distant metastasis or increased OS.
CCRT is a standard treatment for stage III/IV locally 
advanced NPC due to both locoregional control and survival
benefit compared to RT alone. Intergroup Study 0099, in
which concurrent (cisplatin) and adjuvant CTx (5-fluo-
rouracil and cisplatin) were used, showed improved PFS and
OS [9], and randomized clinical trials in endemic areas 
produced similar results [10-12].
Based on these findings, concurrent CTx could be expected
to improve locoregional control and survival rates in selected
early-stage NPC patients. Cheng et al. [13] reported that 
concurrent CTx (5-fluorouracil and cisplatin) achieved a 
locoregional control rate of 100% at 3 years in 32 patients
with AJCC 1997 stage II NPC, whereas RT alone achieved a
locoregional control rate of 91.7% in 12 patients with stage I
or II NPC. Xu et al. [6] retrospectively compared RT alone
with CCRT (cisplatin) in patients with AJCC 2002 T2N1 NPC,
and found concurrent CTx significantly improved locore-
gional control (91.5% vs. 77.3% at 5 years, p=0.008), but not
DMFS or OS. In the present study, concurrent CTx signifi-
cantly improved locoregional control in stage II NPC patients
(Table 3), but this was not reflected by an OS improvement.
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Fig. 2.  Progression-free survival (A) and locoregional relapse-free survival (B) curves according to the use of concurrent
chemotherapy.
This discrepancy may have been caused by the effectiveness
of salvage treatment, as the majority of patients with locore-
gional relapse alone were treated with salvage surgery or RT,
and 5-year OS of patients with locoregional relapse alone
was 42%. However, although a lack of an OS increase miti-
gates against the use of concurrent CTx, its use seems 
warranted based on improved locoregional control, since the
toxicities related to salvage treatments for locoregional 
recurrence after RT alone may be greater than the toxicities
associated with concurrent CTx. A recent phase III trial show-
ed the benefit of CCRT in NPC patients with Chinese 1992
stage II [14], equivalent to AJCC 2010 stage II-III, but only
13% of the study's patients were AJCC stage III. Concurrent 
cisplatin given weekly during RT significantly improved OS
(94.5% vs. 85.8% at 5 years, p=0.007) by reducing distant
metastasis rather than locoregional failure. However, as the
current study showed no difference in DMFS by use of 
concurrent CTx (85.6% vs. 85.4% at 5 years), and there has
not been enough evidence that concurrent CTx can reduce
distant metastasis, follow-up data in a large cohort of early
stage NPC may be needed to assess the effect of concurrent
CTx on distant metastasis.
Conversely, IMRT without any kind of CTx achieves high
locoregional control and OS rates. Su et al. [2] in a Chinese
study reported disease-specific survival, local recurrence-free
survival and DMFS rates were 97.3%, 97.7%, and 97.8%, 
respectively, at 5 years in 198 patients with AJCC 2002 stage
I-IIb NPC treated with IMRT without CTx (141 of these 
patients had stage IIb). Local relapse only occurred in 
patients with T2b disease and their local recurrence-free 
survival rate was 94.2% at 5 years. Tham et al. [15] reported
a 3-year OS of 96.2% in 107 patients, only nine of whom 
received concurrent CTx, with stage IIb NPC treated with
IMRT with or without CTx. However, since most studies 
favoring IMRT alone were reported from single institutional
retrospective experiences in endemic areas, it is unclear
whether IMRT alone is sufficient to treat the stage II NPC,
especially in non-endemic areas.
Neoadjuvant CTx has been used to reduce distant metas-
tasis in locally advanced NPC. Of five randomized controlled
studies using neoadjuvant CTx followed by RT alone, DFS
was increased by neoadjuvant CTx only in one study, and
OS was not improved in any of the studies [16-20]. A meta-
analysis also concluded that neoadjuvant CTx does not 
improve OS [21]. Although neoadjuvant CTx is also used in
early stage NPC, its effect remains unclear. A pooled analysis
of two randomized controlled trials conducted by Chua et
al. [7] in AJCC 1997 stage I and II NPC revealed that induc-
tion CTx (cisplatin, epirubicin, and 5-fluorouracil) improved
OS by 12% (79% vs. 67% at 5 years, p=0.048) by reducing 
distant metastasis (86% vs. 71% at 5 years, p=0.005) in early-
stage NPC (T1-2N0-1). However, Song et al. [8] reported that
induction CTx (cisplatin and 5-fluorouracil) did not improve
clinical outcomes including distant metastasis and OS in
AJCC 1997 stage I and II NPC. In the current study, 24 
patients with AJCC 2002 stage II NPC were treated with
neoadjuvant CTx (mainly cisplatin and 5-fluorouracil) 
followed by RT alone (n=7) or RT combined with concurrent
CTx (n=17). Although the number of patients enrolled in the
current study was small, neoadjuvant CTx did not improve
DMFS or PFS. Tham et al. [15] also found that neoadjuvant
CTx did not improve DMFS in stage IIB NPC.
In addition, delayed definitive RT and toxicities associated
with neoadjuvant CTx could be harmful. Song et al. [8] 
reported that RT delay due to neoadjuvant CTx resulted 
in poorer locoregional control in stage IIB disease than RT
alone (p=0.044). In another trial, in which combination of
bleomycin, epirubicin and cisplatin were used, treatment-
related death was found to be greater for induction CTx than
RT alone (8% vs. 1%) [17]. However, when considering that
distant metastasis is still problematic in early stage NPC, and
earlier studies used old chemotherapeutic regimens, neoad-
juvant CTx with novel agents deserves investigation.
Unlikely concurrent and neoadjuvant CTx, the effect of 
adjuvant CTx on early stage NPC has not been investigated.
In locally advanced NPC, adjuvant CTx after RT alone did
not improve DFS or OS in three randomized trials [22-24].
Instead, adjuvant CTx has been used with CCRT based on
the results of randomized trials, which showed that CCRT
followed by adjuvant CTx significantly improved OS 
compared to RT alone [9-11]. Cheng et al. [13] also used 
adjuvant CTx following CCRT in 32 stage II NPC patients,
but could not investigate the effects of adjuvant CTx due to
the low incidence of distant metastasis. In the present study,
adjuvant CTx was used mainly in the CCRT group, but 
although it was used in 47.6% of patients in this group, it did
not appear to improve PFS or OS (data not shown). Hence,
the efficacy of adjuvant CTx in early stage NPC remains 
unclear.
This study is inherently limited by its retrospective nature.
Another limitation is the change of the staging system: stage
II in the AJCC 2002 staging system consists of IIa (T2aN0)
and IIb (T1N1, T2bN0, T2a/bN1), but T2aN0 was moved to
stage I in AJCC 2010 staging system [25]. T2a and T2b disease
could not be analyzed separately because of the lack of 
information. Epstein-Barr virus infection was tested in only
37 of 138 patients (26.8%), in whom the positive rate was
75.7% (28/37). A variety of CTx regimens and RT techniques
were used.
However, this study also has some strengths. Because it
was a multi-institutional study, retrospective bias was prob-
ably reduced. In addition, because the quality of oncologic
management, including imaging techniques, CTx, and RT,
has improved significantly, we included only patients
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treated during the last decade. MRI was used in 75.4% of 
patients for staging, which can discriminate T stage more
than CT. PET-CT was used in 79.0% of patients as an initial
systemic work-up tool, which means that the risk of includ-
ing patients with asymptomatic distant metastasis was lower
than other studies. In addition, since PET-CT was reim-
bursed by national health insurance beginning June 2006 and
used for routine workups thereafter, locoregional or distant
failures were probably detected and treated earlier, which
might have influenced PFS and OS.
Conclusion
In summary, concurrent CTx significantly improved
LRRFS and PFS in stage II NPC, whereas neoadjuvant CTx
did not. These findings need to be confirmed by a random-
ized clinical trial. Furthermore, since distant metastasis 
occurred in 13% of patients and was not reduced by adding
CTx, more effective novel agents are required.
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